Net Income

Avory & Co. enters the crowded ETF market with AVRY, an actively managed fund shunning trends for a concentrated portfolio of high-quality stocks.

Husqvarna's new residential mowers boast major comfort and durability upgrades, heating up the spring sales battle against John Deere, Toro, and Cub Cadet.

After a transformative year with key FDA/EU approvals, Pulsenmore's financials get a one-time boost. Can it now conquer the remote prenatal care market?

Clearwater Paper launches Velora™, a new lightweight paperboard balancing cost, sustainability, and domestic supply to capture the everyday packaging market.

Australian medtech firm 4DMedical lands CE Mark for its revolutionary CT:VQ lung imaging, fueling a major European expansion with a fresh AU$83M investment.

A $15M grant fuels a revolutionary therapy for a fatal childhood disease, turning patients' own cells into 'living biofactories' to fight MPS I.

Amid a tough biotech market, the firm extends its cash runway to 2027, accelerating development of its promising rademikibart treatment for respiratory diseases.

Neumora reveals promising data for Alzheimer's and schizophrenia drugs, but a delay in its obesity program highlights the high-stakes world of biotech.

As millions grapple with Cannabis Use Disorder, a small biotech's lead drug enters Phase 3 trials, promising the first-ever FDA-approved treatment.

PMGC Holdings touts major acquisitions and a promising biotech pipeline, but a look at its financials reveals a high-stakes bet on future growth.

Magnachip's new power semiconductors promise major efficiency and density gains for servers, tackling the soaring energy needs of the growing AI boom.

NUCOT celebrates patients thriving 25+ years post-transplant, setting new global benchmarks in survival rates through advanced care and resilience.

An Australian startup's new AI trading platform promises to master crypto volatility, but it enters a crowded market facing security and regulatory hurdles.

Big Rock Brewery reverses years of losses, posting a $5.8M EBITDA gain and a 35% sales volume surge, signaling a powerful strategic turnaround.

Over 3.5 million Africans suffer from psoriasis with little support. A historic forum in Nairobi aims to shatter the silence and forge a new path for care.

Global CRO ChemPartner launches a new research site in Kent's Discovery Park, a major strategic push to accelerate drug development for European clients.

A new report reveals a major shift in cybercrime, with attackers now preferring stolen credentials over hacking to breach corporate networks.

Equasens reports a 9.1% revenue jump, driven by AI investment and key acquisitions, as the company navigates a major leadership change and market shifts.

After a record year, PayPoint is restructuring into four focused units. The move aims to boost shareholder value and adapt to a fast-changing digital world.

A new global guide offers a 'try before you buy' approach for regulators, aiming to fix a broken market and unlock billions in high-integrity climate finance.